DUBLIN, March 15, 2021 . ResearchAndMarkets.com’s offering.
One of the fastest changing and dynamic markets, the global market for QC cell and gene manufacturing is expected to grow at a CAGR of 22.80% over the projected period 2020-2030.
The market is driven by specific factors, which include an increase in cancer and breast diseases, an increase in clinical trials for cell and gene therapy, stable investment and consolidation in the cell and gene therapy market. , and a favorable regulatory environment stimulates the growth of the global cell and gene QC manufacturing market.
Manufacturing, as a sign of enabling advanced therapies to be distributed across the patient population, is a consistent driving force behind the growth of total adoption of innovative therapies. Quality control is an essential part of manufacturing, especially considering advanced therapies such as cell and gene therapies. Generating profit to one side, the cost of treatment can be controlled by ensuring manufacturing costs.
This must also increase cost in the fundamental factors, including quality control. While most regulators currently order rapid test technologies, CDMO juggernauts have already begun offering services and products based on advanced technologies such as GNA and PCR.
Not only as an attractive incentive tool to gather more cell and gene innovators, but these market leaders are also leading consolidation within the industry by getting smaller companies that are offer specific products and services. As a result, there is tremendous dynamism in the market, giving full access to cell and gene therapies even in less developed countries.
Within the research report, the market is segmented according to results, processes, analysis methods, technologies and area. Each of these segments covers a picture of the market over the projected years, market revenue bias, underlying patterns, and trends using analysis of the primary and secondary data. -school received.
Competitive Landscape
Rapid technological developments and the simultaneous adoption among leading companies have made global cell and gene QC manufacturing market one of the most beneficial opportunities for large companies within the therapeutic medicine biosphere. With both market juggernauts and emerging companies playing an important role in the market, this industry is fast growing into a market that is very beneficial for both manufacturers and consumers. last.
Although mostly based Europe, market leaders such as Merck KGaA and Lonza Group AG, have been at the forefront of enabling cell and gene manufacturing capabilities across North America and the Asia-Pacific departments.
On an area basis, North America maintains the largest share of QC cell and gene manufacturing market due to high number of active cell and gene clinical trials, large government funding, expansion activities with major companies, and high overall adoption rate for advanced medicines. In addition, Asia-Pacific the region is expected to grow at the fastest CAGR in the forecast period, 2020-2030.
Key questions answered in this report:
- What are the key drivers, challenges, and market opportunities and their implications in the global cell and gene QC manufacturing market?
- What is the potential impact of advances in QC in the contract development and manufacturing organization among cell and gene innovators?
- What is the current market demand along with the expected future demand for the global QC cell and gene manufacturing market?
- What are the key regulatory barriers for business players looking to enter this highly vibrant market?
- What are the key development strategies implemented by the key players to maintain the competitive market?
- How each of the following market segments is expected to grow in the projected period from 2020 to 2030:
- Who are the key players with major offers to the global cell and gene manufacturing QC market? What market leadership is expected for each of these key players?
- What emerging companies are expected to be the most upset in the future, and what are their key strategies for sustainable growth in the global cell and gene QC manufacturing market?
- How is the automation of challenges expected to change up in the market?
- What is the cost of QC vs production cost for cell and gene therapies and what strategies are key players adopting to increase profits?
Key topics covered:
1 Product Definition and Market Area
2 Research Methodology
3 Market forecast
3.1 The Clinical Significance of Cell and Gene Therapies
3.2 manufacturing of cell and gene therapy QC: An industry overview
3.3 Find the market
3.4 Impact of COVID-19
4 Market Dynamics
4.1 Impact Analysis
4.2 Market drivers
4.2.1 Increase in incidence of cancer and chronic diseases
4.2.2 Rising number of clinical trials
4.2.3 Stable investment and consolidation in the cell and gene treatment market
4.2.4 A favorable regulatory environment
4.3 Market barriers
4.3.1 Lack of Reliable Vector Production for cell and gene therapy
4.3.2 Lack of specific assessments of treatment
4.4 Opportunity
4.4.1 Consolidation of drugs and a strong pipeline of cell and gene therapies
4.4.2 Multiple investments in expanding cGMP units
5 Business Perspectives
5.1 The role of regulatory bodies and the consortium in cell and gene therapy
5.1.1 Regulatory Challenges
5.1.2 Successful Management Strategies
5.2 Governance Framework
5.2.1 Chemistry, Manufacturing and Control (CMC) Requirements by the FDA
5.2.1.1 Product Testing
5.2.1.1.1 Microbial Test
5.2.1.1.2 Identity
5.2.1.1.3 Purity
5.2.1.1.4 Comas
5.2.1.1.5 Work Capability
5.2.1.1.6 Cell number / dose
5.2.2 Quality issues of cell and gene treatment products with the EMA
5.2.2.1 Character
5.2.2.1.1 Identity Test
5.2.2.1.2 Purity Test
5.2.2.1.3 Aptitude Test
5.2.2.1.4 Distribution Criteria
5.2.3 Quality control requirements for cell and gene therapies in China
5.2.3.1 CAR-T cell therapy
5.2.3.2 Gene Medicine
5.3 Cost Analysis for Cell Treatment and Gene QC
6 Global cell and gene manufacturing QC market: competitive perspectives
6.1 Preview
6.2 Synergistic Actions
6.3 Extension Actions
6.4 Product and Service Launch
6.5 Construction
6.6 Other developments
6.7 Market Share Analysis, 2019-2020
6.8 Growth Share Analysis
6.8.1 Growth Share Analysis (by Company)
6.8.2 Growth Share Analysis (by Technology)
6.8.3 Growth Share Analysis (by Monitoring Method)
7 Global Cell Manufacturing and Gene Therapy QC Market (by Product and Service), $ Million, 2019-2030
7.1 Preview
7.2 Service
7.3 Products
8 Global Cell and Gene Therapy QC Market (by Process), $ Million, 2019-2030
8.1 Preview
8.2 Preparing starting material
8.3 Upward processing
8.4 Downstream processing
9 Global Manufacturing and Gene Therapy QC QC Market (by Study Method), $ Million, 2019-2030
9.1 Preview
9.2 Safety Test
9.3 Purity Test
9.4 Potency Test
9.5 Identity Test
9.6 Sustainability Test
10 Global Cell and Gene Therapy (with Technology) QC Market, $ Million, 2019-2030
10.1 Preview
10.2 Polymerase chain reaction
10.3 Stream Cytometry
10.4 Limulus Amebocyte Lysate (LAL)
10.5 Enzyme Binding Immunosorbent Assay (ELISA)
10.6 Chromatography
10.7 Mass Spectrometry
10.8 Western Blot
10.9 Next generation sequence
10.1 Electrophoresis
10.11 Other technologies
11 Global Cell Manufacturing and Therapy QC Market (by area), $ Million, 2019-2030
12 Company Profiles
- Corporate Bio-Techne
- bioMerieux SA
- Catalent, Inc.
- Charles River Laboratories International Inc.
- Eurofins Science SE
- F. Hoffmann-La Roche Ltd.
- Intertek Group plc
- Lonza AG Group
- Merck KGaA
- Sartorius AG
- SGS SA
- Sistemic Scotland Limited
- Thermo Fisher Scientific Inc.
- Vigene Biology, Inc.
- AppTec WuXi
For more information about this report, visit https://www.researchandmarkets.com/r/dpen0h
Contact the media:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For EST Office Hours Call + 1-917-300-0470
For US / CAN Toll Free Call + 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax USA: 646-607-1907
Fax (outside the US): +353-1-481-1716
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com